Attached files
file | filename |
---|---|
8-K - FORM 8-K - NxStage Medical, Inc. | b87255e8vk.htm |
Exhibit 99.1
BARRY M. STRAUBE, M.D. , FORMER MEDICARE OFFICIAL AND LEADER OF
MAJOR QUALITY AND POLICY INITIATIVES IN NEPHROLOGY, JOINS
NXSTAGE BOARD OF DIRECTORS
MAJOR QUALITY AND POLICY INITIATIVES IN NEPHROLOGY, JOINS
NXSTAGE BOARD OF DIRECTORS
LAWRENCE, Mass., July 12, 2011 NxStage® Medical, Inc. (Nasdaq: NXTM), a leading
manufacturer of innovative dialysis products, today announced the appointment of Barry M. Straube,
M.D., to its Board of Directors.
Dr. Straube is the Immediate Past Chief Medical Officer for the Centers for Medicare & Medicaid
Services (CMS), as well as the Immediate Past Director of the CMS Office of Clinical Standards &
Quality (OCSQ). In his role as the most senior clinical advisor to CMS, Dr. Straube and his office
spearheaded key initiatives including Medicare coverage decision-making, multiple national quality
improvement collaboratives, CMS clinical quality measurement and information technology efforts,
defining quality standards for U.S. healthcare facilities, development of Value-Based Purchasing
models, and implementation of many sections of the Affordable Care Act of 2010. Dr. Straube also
Chaired the End Stage Renal Disease (ESRD) and Clinical Laboratory Open Door Forum and acted as a
senior advisor on ESRD and transplantation issues to the agency. Dr. Straube retired from CMS in
February, 2011.
Earlier, Dr. Straube was Vice President of Quality Improvement at Health Net, one of the industrys
largest HMOs, and the CMS Regional Chief Medical Officer for California, Arizona, Nevada, Hawaii
and far Pacific Territories. Dr. Straube received an A.B. degree (magna cum laude, Phi Beta Kappa)
from Princeton University and received his M.D. degree from the University of Michigan Medical
School. Dr. Straube completed an internal medicine residency at California Pacific Medical Center
in San Francisco, where he later served as Chief of the Division of Nephrology. He has also served
as a Renal Fellow at Tufts University-New England Medical Center in Boston.
Barry is a tremendous and timely addition to the NxStage Board, bringing demonstrated and
recognized leadership in the healthcare public policy arena, said Jeffrey Burbank, Chief Executive
Officer, NxStage Medical, Inc. He will provide NxStage and our Board with invaluable guidance as
we advance our long term growth strategy and continue to mature reimbursement for more frequent
home hemodialysis with the System One.
Ive known NxStage for many years and have a great deal of respect for their discipline in
developing the clinical and economic fact base to support home, more frequent hemodialysis with the
System One, said Dr. Straube. I truly believe that home, more frequent hemodialysis can play a
significant part in achieving Medicares goals for patient-centered care that leads to better
health outcomes and associated lower costs. Im excited to bring a unique perspective to the Board
and look forward to working with the Board, Jeff, and the management team to advance NxStages
vision.
About the NxStage System One
About the size of a 13-inch tube television, the NxStage System One is the first and only
truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration
(FDA). Its simplicity and compact size are intended to allow easy use in patients homes and give
patients the opportunity to travel with their therapy. It plugs into standard electrical outlets
and, unlike conventional hemodialysis systems, requires no special infrastructure to operate. Under
the guidance of their physician, patients can use the NxStage System One, with their trained
partners, where, how and when it best meets their needs, at home or on vacation.
About NxStage Medical, Inc.
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence,
Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment
of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its
products, please visit NxStages website at www.nxstage.com.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements contained in this release that are not clearly
historical in nature are forward-looking, and the words anticipate, believe, expect,
estimate, plan, and similar expressions are generally intended to identify forward-looking
statements. Examples of these forward-looking statements include statements as to the contributions
Dr. Straube will make to NxStages performance and operating results. All forward-looking
statements involve risks, uncertainties and contingencies, many of which are beyond NxStages
control, which may cause actual results, performance, or achievements to differ materially from
anticipated results, performance or achievements. Certain factors which may affect future operating
results are detailed in NxStages filings with the Securities and Exchange Commission, including
the Quarterly Report on Form 10-Q for the period ending March 31, 2011. In addition, the statements
in this press release represent NxStages expectations and beliefs as of the date of this press
release. NxStage anticipates that subsequent events and developments may cause these expectations
and beliefs to change. However, while NxStage may elect to update these forward-looking statements
at some point in the future, it specifically disclaims any obligation to do so, whether as a result
of new information, future events, or otherwise. These forward-looking statements should not be
relied upon as representing NxStages expectations or beliefs as of any date subsequent to the date
of this press release.
Media Contact:
Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.
ir@nxstage.com
978-332-5923
Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.
ir@nxstage.com
978-332-5923